Effects of tofersen treatment in patients with <i>SOD1</i>-ALS in a “real-world” setting - a 12-month multicenter cohort study from the German early access program

Background - In April 2023, the antisense oligonucleotide tofersen was approved by the U.S. Food and Drug Administration (FDA) for treatment of SOD1-amyotrophic lateral sclerosis (ALS), after a decrease of neurofilament light chain (NfL) levels had been demonstrated. - Methods - Between 03/2022 and...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Wiesenfarth, Maximilian (VerfasserIn) , Dorst, Johannes (VerfasserIn) , Brenner, David (VerfasserIn) , Elmas, Zeynep (VerfasserIn) , Parlak, Özlem (VerfasserIn) , Uzelac, Zeljko (VerfasserIn) , Kandler, Katharina (VerfasserIn) , Mayer, Kristina (VerfasserIn) , Weiland, Ulrike (VerfasserIn) , Herrmann, Christine (VerfasserIn) , Schuster, Joachim (VerfasserIn) , Freischmidt, Axel (VerfasserIn) , Müller, Kathrin (VerfasserIn) , Siebert, Reiner (VerfasserIn) , Bachhuber, Franziska (VerfasserIn) , Simak, Tatiana (VerfasserIn) , Günther, Kornelia (VerfasserIn) , Fröhlich, Elke (VerfasserIn) , Knehr, Antje (VerfasserIn) , Regensburger, Martin (VerfasserIn) , German, Alexander (VerfasserIn) , Petri, Susanne (VerfasserIn) , Grosskreutz, Julian (VerfasserIn) , Klopstock, Thomas (VerfasserIn) , Reilich, Peter (VerfasserIn) , Schöberl, Florian (VerfasserIn) , Hagenacker, Tim (VerfasserIn) , Weyen, Ute (VerfasserIn) , Günther, René (VerfasserIn) , Vidovic, Maximilian (VerfasserIn) , Jentsch, Martin (VerfasserIn) , Haarmeier, Thomas (VerfasserIn) , Weydt, Patrick (VerfasserIn) , Valkadinov, Ivan (VerfasserIn) , Hesebeck-Brinckmann, Jasper (VerfasserIn) , Conrad, Julian (VerfasserIn) , Weishaupt, Jochen H. (VerfasserIn) , Schumann, Peggy (VerfasserIn) , Körtvélyessy, Peter (VerfasserIn) , Meyer, Thomas (VerfasserIn) , Ruf, Wolfgang Philipp (VerfasserIn) , Witzel, Simon (VerfasserIn) , Senel, Makbule (VerfasserIn) , Tumani, Hayrettin (VerfasserIn) , Ludolph, Albert Christian (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: March 2024
In: EClinicalMedicine
Year: 2024, Jahrgang: 69, Pages: 1-12
ISSN:2589-5370
DOI:10.1016/j.eclinm.2024.102495
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.eclinm.2024.102495
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2589537024000749
Volltext
Verfasserangaben:Maximilian Wiesenfarth, Johannes Dorst, David Brenner, Zeynep Elmas, Özlem Parlak, Zeljko Uzelac, Katharina Kandler, Kristina Mayer, Ulrike Weiland, Christine Herrmann, Joachim Schuster, Axel Freischmidt, Kathrin Müller, Reiner Siebert, Franziska Bachhuber, Tatiana Simak, Kornelia Günther, Elke Fröhlich, Antje Knehr, Martin Regensburger, Alexander German, Susanne Petri, Julian Grosskreutz, Thomas Klopstock, Peter Reilich, Florian Schöberl, Tim Hagenacker, Ute Weyen, René Günther, Maximilian Vidovic, Martin Jentsch, Thomas Haarmeier, Patrick Weydt, Ivan Valkadinov, Jasper Hesebeck-Brinckmann, Julian Conrad, Jochen Hans Weishaupt, Peggy Schumann, Peter Körtvélyessy, Thomas Meyer, Wolfgang Philipp Ruf, Simon Witzel, Makbule Senel, Hayrettin Tumani, Albert Christian Ludolph

MARC

LEADER 00000caa a2200000 c 4500
001 1919613102
003 DE-627
005 20250717000711.0
007 cr uuu---uuuuu
008 250312s2024 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.eclinm.2024.102495  |2 doi 
035 |a (DE-627)1919613102 
035 |a (DE-599)KXP1919613102 
035 |a (OCoLC)1528020190 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Wiesenfarth, Maximilian  |d 1990-  |e VerfasserIn  |0 (DE-588)1198946431  |0 (DE-627)1681159201  |4 aut 
245 1 0 |a Effects of tofersen treatment in patients with <i>SOD1</i>-ALS in a “real-world” setting - a 12-month multicenter cohort study from the German early access program  |c Maximilian Wiesenfarth, Johannes Dorst, David Brenner, Zeynep Elmas, Özlem Parlak, Zeljko Uzelac, Katharina Kandler, Kristina Mayer, Ulrike Weiland, Christine Herrmann, Joachim Schuster, Axel Freischmidt, Kathrin Müller, Reiner Siebert, Franziska Bachhuber, Tatiana Simak, Kornelia Günther, Elke Fröhlich, Antje Knehr, Martin Regensburger, Alexander German, Susanne Petri, Julian Grosskreutz, Thomas Klopstock, Peter Reilich, Florian Schöberl, Tim Hagenacker, Ute Weyen, René Günther, Maximilian Vidovic, Martin Jentsch, Thomas Haarmeier, Patrick Weydt, Ivan Valkadinov, Jasper Hesebeck-Brinckmann, Julian Conrad, Jochen Hans Weishaupt, Peggy Schumann, Peter Körtvélyessy, Thomas Meyer, Wolfgang Philipp Ruf, Simon Witzel, Makbule Senel, Hayrettin Tumani, Albert Christian Ludolph 
264 1 |c March 2024 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online verfügbar: 15. Februar 2024, Artikelversion: 15. Februar 2024 
500 |a Gesehen am 12.03.2025 
520 |a Background - In April 2023, the antisense oligonucleotide tofersen was approved by the U.S. Food and Drug Administration (FDA) for treatment of SOD1-amyotrophic lateral sclerosis (ALS), after a decrease of neurofilament light chain (NfL) levels had been demonstrated. - Methods - Between 03/2022 and 04/2023, 24 patients with SOD1-ALS from ten German ALS reference centers were followed-up until the cut-off date for ALS functional rating scale revised (ALSFRS-R), progression rate (loss of ALSFRS-R/month), NfL, phosphorylated neurofilament heavy chain (pNfH) in cerebrospinal fluid (CSF), and adverse events. - Findings - During the observation period, median ALSFRS-R decreased from 38.0 (IQR 32.0-42.0) to 35.0 (IQR 29.0-42.0), corresponding to a median progression rate of 0.11 (IQR −0.09 to 0.32) points of ALSFRS-R lost per month. Median serum NfL declined from 78.0 pg/ml (IQR 37.0-147.0 pg/ml; n = 23) to 36.0 pg/ml (IQR 22.0-65.0 pg/ml; n = 23; p = 0.02), median pNfH in CSF from 2226 pg/ml (IQR 1061-6138 pg/ml; n = 18) to 1151 pg/ml (IQR 521-2360 pg/ml; n = 18; p = 0.02). In the CSF, we detected a pleocytosis in 73% of patients (11 of 15) and an intrathecal immunoglobulin synthesis (IgG, IgM, or IgA) in 9 out of 10 patients. Two drug-related serious adverse events were reported. - Interpretation - Consistent with the VALOR study and its Open Label Extension (OLE), our results confirm a reduction of NfL serum levels, and moreover show a reduction of pNfH in CSF. The therapy was safe, as no persistent symptoms were observed. Pleocytosis and Ig synthesis in CSF with clinical symptoms related to myeloradiculitis in two patients, indicate the potential of an autoimmune reaction. - Funding - No funding was received towards this study. 
650 4 |a Amyotrophic lateral sclerosis 
650 4 |a Antisense oligonucleotide 
650 4 |a Early access program 
650 4 |a Tofersen 
700 1 |a Dorst, Johannes  |e VerfasserIn  |4 aut 
700 1 |a Brenner, David  |e VerfasserIn  |4 aut 
700 1 |a Elmas, Zeynep  |e VerfasserIn  |4 aut 
700 1 |a Parlak, Özlem  |e VerfasserIn  |4 aut 
700 1 |a Uzelac, Zeljko  |e VerfasserIn  |4 aut 
700 1 |a Kandler, Katharina  |e VerfasserIn  |4 aut 
700 1 |a Mayer, Kristina  |e VerfasserIn  |4 aut 
700 1 |a Weiland, Ulrike  |e VerfasserIn  |4 aut 
700 1 |a Herrmann, Christine  |e VerfasserIn  |4 aut 
700 1 |a Schuster, Joachim  |e VerfasserIn  |4 aut 
700 1 |a Freischmidt, Axel  |e VerfasserIn  |4 aut 
700 1 |a Müller, Kathrin  |e VerfasserIn  |4 aut 
700 1 |a Siebert, Reiner  |e VerfasserIn  |4 aut 
700 1 |a Bachhuber, Franziska  |e VerfasserIn  |4 aut 
700 1 |a Simak, Tatiana  |e VerfasserIn  |4 aut 
700 1 |a Günther, Kornelia  |e VerfasserIn  |4 aut 
700 1 |a Fröhlich, Elke  |e VerfasserIn  |4 aut 
700 1 |a Knehr, Antje  |e VerfasserIn  |4 aut 
700 1 |a Regensburger, Martin  |e VerfasserIn  |4 aut 
700 1 |a German, Alexander  |e VerfasserIn  |4 aut 
700 1 |a Petri, Susanne  |e VerfasserIn  |4 aut 
700 1 |a Grosskreutz, Julian  |e VerfasserIn  |4 aut 
700 1 |a Klopstock, Thomas  |e VerfasserIn  |4 aut 
700 1 |a Reilich, Peter  |e VerfasserIn  |4 aut 
700 1 |a Schöberl, Florian  |e VerfasserIn  |4 aut 
700 1 |a Hagenacker, Tim  |e VerfasserIn  |4 aut 
700 1 |a Weyen, Ute  |e VerfasserIn  |4 aut 
700 1 |a Günther, René  |e VerfasserIn  |4 aut 
700 1 |a Vidovic, Maximilian  |e VerfasserIn  |4 aut 
700 1 |a Jentsch, Martin  |e VerfasserIn  |4 aut 
700 1 |a Haarmeier, Thomas  |e VerfasserIn  |4 aut 
700 1 |a Weydt, Patrick  |e VerfasserIn  |4 aut 
700 1 |a Valkadinov, Ivan  |e VerfasserIn  |0 (DE-588)1275314384  |0 (DE-627)1826773231  |4 aut 
700 1 |a Hesebeck-Brinckmann, Jasper  |d 1995-  |e VerfasserIn  |0 (DE-588)1349350052  |0 (DE-627)1909505617  |4 aut 
700 1 |a Conrad, Julian  |d 1984-  |e VerfasserIn  |0 (DE-588)1045448508  |0 (DE-627)774514965  |0 (DE-576)399216510  |4 aut 
700 1 |a Weishaupt, Jochen H.  |d 1971-  |e VerfasserIn  |0 (DE-588)122148924  |0 (DE-627)705789039  |0 (DE-576)293117810  |4 aut 
700 1 |a Schumann, Peggy  |e VerfasserIn  |4 aut 
700 1 |a Körtvélyessy, Peter  |e VerfasserIn  |4 aut 
700 1 |a Meyer, Thomas  |e VerfasserIn  |4 aut 
700 1 |a Ruf, Wolfgang Philipp  |e VerfasserIn  |4 aut 
700 1 |a Witzel, Simon  |e VerfasserIn  |4 aut 
700 1 |a Senel, Makbule  |e VerfasserIn  |4 aut 
700 1 |a Tumani, Hayrettin  |e VerfasserIn  |4 aut 
700 1 |a Ludolph, Albert Christian  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t EClinicalMedicine  |d Amsterdam : Elsevier, 2018  |g 69(2024), Artikel-ID 102495, Seite 1-12  |h Online-Ressource  |w (DE-627)1035271834  |w (DE-600)2946413-4  |w (DE-576)512181683  |x 2589-5370  |7 nnas  |a Effects of tofersen treatment in patients with <i>SOD1</i>-ALS in a “real-world” setting - a 12-month multicenter cohort study from the German early access program 
773 1 8 |g volume:69  |g year:2024  |g elocationid:102495  |g pages:1-12  |g extent:12  |a Effects of tofersen treatment in patients with <i>SOD1</i>-ALS in a “real-world” setting - a 12-month multicenter cohort study from the German early access program 
856 4 0 |u https://doi.org/10.1016/j.eclinm.2024.102495  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S2589537024000749  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20250312 
993 |a Article 
994 |a 2024 
998 |g 122148924  |a Weishaupt, Jochen H.  |m 122148924:Weishaupt, Jochen H.  |d 60000  |d 62700  |e 60000PW122148924  |e 62700PW122148924  |k 0/60000/  |k 1/60000/62700/  |p 37 
998 |g 1045448508  |a Conrad, Julian  |m 1045448508:Conrad, Julian  |d 60000  |d 62700  |d 60000  |e 60000PC1045448508  |e 62700PC1045448508  |e 60000PC1045448508  |k 0/60000/  |k 1/60000/62700/  |k 0/60000/  |p 36 
998 |g 1349350052  |a Hesebeck-Brinckmann, Jasper  |m 1349350052:Hesebeck-Brinckmann, Jasper  |d 60000  |d 62700  |e 60000PH1349350052  |e 62700PH1349350052  |k 0/60000/  |k 1/60000/62700/  |p 35 
998 |g 1275314384  |a Valkadinov, Ivan  |m 1275314384:Valkadinov, Ivan  |d 60000  |e 60000PV1275314384  |k 0/60000/  |p 34 
999 |a KXP-PPN1919613102  |e 4686288657 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"title":[{"title_sort":"EClinicalMedicine","title":"EClinicalMedicine"}],"part":{"extent":"12","volume":"69","text":"69(2024), Artikel-ID 102495, Seite 1-12","pages":"1-12","year":"2024"},"pubHistory":["Volume 1 (July 2018)-"],"recId":"1035271834","language":["eng"],"disp":"Effects of tofersen treatment in patients with <i>SOD1</i>-ALS in a “real-world” setting - a 12-month multicenter cohort study from the German early access programEClinicalMedicine","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 28.05.2020"],"id":{"eki":["1035271834"],"zdb":["2946413-4"],"issn":["2589-5370"]},"origin":[{"publisherPlace":"Amsterdam","dateIssuedDisp":"[2018]-","publisher":"Elsevier"}],"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"12 S."}],"name":{"displayForm":["Maximilian Wiesenfarth, Johannes Dorst, David Brenner, Zeynep Elmas, Özlem Parlak, Zeljko Uzelac, Katharina Kandler, Kristina Mayer, Ulrike Weiland, Christine Herrmann, Joachim Schuster, Axel Freischmidt, Kathrin Müller, Reiner Siebert, Franziska Bachhuber, Tatiana Simak, Kornelia Günther, Elke Fröhlich, Antje Knehr, Martin Regensburger, Alexander German, Susanne Petri, Julian Grosskreutz, Thomas Klopstock, Peter Reilich, Florian Schöberl, Tim Hagenacker, Ute Weyen, René Günther, Maximilian Vidovic, Martin Jentsch, Thomas Haarmeier, Patrick Weydt, Ivan Valkadinov, Jasper Hesebeck-Brinckmann, Julian Conrad, Jochen Hans Weishaupt, Peggy Schumann, Peter Körtvélyessy, Thomas Meyer, Wolfgang Philipp Ruf, Simon Witzel, Makbule Senel, Hayrettin Tumani, Albert Christian Ludolph"]},"id":{"eki":["1919613102"],"doi":["10.1016/j.eclinm.2024.102495"]},"origin":[{"dateIssuedDisp":"March 2024","dateIssuedKey":"2024"}],"recId":"1919613102","language":["eng"],"note":["Online verfügbar: 15. Februar 2024, Artikelversion: 15. Februar 2024","Gesehen am 12.03.2025"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"display":"Wiesenfarth, Maximilian","roleDisplay":"VerfasserIn","role":"aut","family":"Wiesenfarth","given":"Maximilian"},{"given":"Johannes","family":"Dorst","role":"aut","display":"Dorst, Johannes","roleDisplay":"VerfasserIn"},{"given":"David","family":"Brenner","role":"aut","roleDisplay":"VerfasserIn","display":"Brenner, David"},{"role":"aut","display":"Elmas, Zeynep","roleDisplay":"VerfasserIn","given":"Zeynep","family":"Elmas"},{"given":"Özlem","family":"Parlak","role":"aut","display":"Parlak, Özlem","roleDisplay":"VerfasserIn"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Uzelac, Zeljko","given":"Zeljko","family":"Uzelac"},{"role":"aut","display":"Kandler, Katharina","roleDisplay":"VerfasserIn","given":"Katharina","family":"Kandler"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Mayer, Kristina","given":"Kristina","family":"Mayer"},{"given":"Ulrike","family":"Weiland","role":"aut","roleDisplay":"VerfasserIn","display":"Weiland, Ulrike"},{"given":"Christine","family":"Herrmann","role":"aut","display":"Herrmann, Christine","roleDisplay":"VerfasserIn"},{"given":"Joachim","family":"Schuster","role":"aut","display":"Schuster, Joachim","roleDisplay":"VerfasserIn"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Freischmidt, Axel","given":"Axel","family":"Freischmidt"},{"display":"Müller, Kathrin","roleDisplay":"VerfasserIn","role":"aut","family":"Müller","given":"Kathrin"},{"given":"Reiner","family":"Siebert","role":"aut","roleDisplay":"VerfasserIn","display":"Siebert, Reiner"},{"given":"Franziska","family":"Bachhuber","role":"aut","roleDisplay":"VerfasserIn","display":"Bachhuber, Franziska"},{"roleDisplay":"VerfasserIn","display":"Simak, Tatiana","role":"aut","family":"Simak","given":"Tatiana"},{"given":"Kornelia","family":"Günther","role":"aut","roleDisplay":"VerfasserIn","display":"Günther, Kornelia"},{"role":"aut","display":"Fröhlich, Elke","roleDisplay":"VerfasserIn","given":"Elke","family":"Fröhlich"},{"display":"Knehr, Antje","roleDisplay":"VerfasserIn","role":"aut","family":"Knehr","given":"Antje"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Regensburger, Martin","given":"Martin","family":"Regensburger"},{"role":"aut","display":"German, Alexander","roleDisplay":"VerfasserIn","given":"Alexander","family":"German"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Petri, Susanne","given":"Susanne","family":"Petri"},{"given":"Julian","family":"Grosskreutz","role":"aut","display":"Grosskreutz, Julian","roleDisplay":"VerfasserIn"},{"display":"Klopstock, Thomas","roleDisplay":"VerfasserIn","role":"aut","family":"Klopstock","given":"Thomas"},{"given":"Peter","family":"Reilich","role":"aut","roleDisplay":"VerfasserIn","display":"Reilich, Peter"},{"given":"Florian","family":"Schöberl","role":"aut","display":"Schöberl, Florian","roleDisplay":"VerfasserIn"},{"display":"Hagenacker, Tim","roleDisplay":"VerfasserIn","role":"aut","family":"Hagenacker","given":"Tim"},{"family":"Weyen","given":"Ute","display":"Weyen, Ute","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Günther, René","given":"René","family":"Günther"},{"given":"Maximilian","family":"Vidovic","role":"aut","display":"Vidovic, Maximilian","roleDisplay":"VerfasserIn"},{"given":"Martin","family":"Jentsch","role":"aut","display":"Jentsch, Martin","roleDisplay":"VerfasserIn"},{"given":"Thomas","family":"Haarmeier","role":"aut","roleDisplay":"VerfasserIn","display":"Haarmeier, Thomas"},{"display":"Weydt, Patrick","roleDisplay":"VerfasserIn","role":"aut","family":"Weydt","given":"Patrick"},{"role":"aut","display":"Valkadinov, Ivan","roleDisplay":"VerfasserIn","given":"Ivan","family":"Valkadinov"},{"family":"Hesebeck-Brinckmann","given":"Jasper","display":"Hesebeck-Brinckmann, Jasper","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Conrad, Julian","role":"aut","family":"Conrad","given":"Julian"},{"family":"Weishaupt","given":"Jochen H.","roleDisplay":"VerfasserIn","display":"Weishaupt, Jochen H.","role":"aut"},{"given":"Peggy","family":"Schumann","role":"aut","display":"Schumann, Peggy","roleDisplay":"VerfasserIn"},{"given":"Peter","family":"Körtvélyessy","role":"aut","roleDisplay":"VerfasserIn","display":"Körtvélyessy, Peter"},{"roleDisplay":"VerfasserIn","display":"Meyer, Thomas","role":"aut","family":"Meyer","given":"Thomas"},{"roleDisplay":"VerfasserIn","display":"Ruf, Wolfgang Philipp","role":"aut","family":"Ruf","given":"Wolfgang Philipp"},{"family":"Witzel","given":"Simon","display":"Witzel, Simon","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Senel","given":"Makbule","display":"Senel, Makbule","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","display":"Tumani, Hayrettin","roleDisplay":"VerfasserIn","given":"Hayrettin","family":"Tumani"},{"display":"Ludolph, Albert Christian","roleDisplay":"VerfasserIn","role":"aut","family":"Ludolph","given":"Albert Christian"}],"title":[{"title":"Effects of tofersen treatment in patients with <i>SOD1</i>-ALS in a “real-world” setting - a 12-month multicenter cohort study from the German early access program","title_sort":"Effects of tofersen treatment in patients with <i>SOD1</i>-ALS in a “real-world” setting - a 12-month multicenter cohort study from the German early access program"}]} 
SRT |a WIESENFARTEFFECTSOFT2024